体育博彩

Akeso Released Complete Phase 3 Data for Gumokimab (AK111, IL-17) in Moderate to Severe Plaque Psoriasis
2024-10-28
Akeso Released Complete Phase 3 Data for Gumokimab (AK111, IL-17) in Moderate to Severe Plaque Psoriasis
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
2024-10-16
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
2024-10-13
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
2024-09-30
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China
2024-09-30
Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China
ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC
2024-09-18
ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC
ESMO 2024 | Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety
2024-09-18
ESMO 2024 | Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety
ESMO 2024 | Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1–Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2024-09-18
ESMO 2024 | Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1–Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
WCLC 2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session
2024-09-09
WCLC 2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session
WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled
2024-09-08
WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
2024-09-06
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
2024-08-29
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
ladbrokes立博 澳彩网 im电竞 赌博平台 亚洲博彩app